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ABSTRACT
Methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase (TS) play key roles in intracellular
folate metabolism. Polymorphisms in these enzymes have been shown to modify toxicity of methotrexate
(MTX) after hematopoietic cell transplantation. In this study, we evaluated the risk of acute graft-versus-host
disease (GVHD) associated with genetic variation in recipient and donor MTHFR and TS genotypes to assess
whether genotype alters the efficacy of MTX in acute GVHD prophylaxis. Data on the transplantation course
were abstracted from medical records for 304 adults who received allogeneic hematopoietic cell transplants.
MTHFR (C677T and A1298C ) and TS (enhancer-region 28-base pair repeat, TSER, and 1494del6) genotypes
were determined using polymerase chain reaction/restriction fragment length polymorphism and TaqMan
assays. Multivariable logistic regression was used to assess the associations between genotypes and risk of acute
GVHD. Compared with recipients with the wild-type MTHFR 677CC genotype, those with the variant 677T
allele showed a decreased risk of detectable acute GVHD (677CT: odds ratio, 0.8; 95% confidence interval,
0.4-1.6; 677TT: odds ratio, 0.4; 95% confidence interval, 0.2-0.8; P for trend  .01). The variant MTHFR
1298C allele in recipients was associated with an increased risk of acute GVHD compared with the wild-type
MTHFR 1298AA genotype (1298AC: odds ratio, 2.0; 95% confidence interval, 1.1-3.9; 1298CC: odds ratio, 3.6;
95% confidence interval, 1.0-12.7; P for trend < .01). No association with risk of acute GVHD was observed
for donorMTHFR genotypes or for recipient or donor TS genotypes, with the exception of an increase in acute
GVHD among recipients whose donors had the TSER 3R/2R genotype (odds ratio, 3.0; 95% confidence
interval, 1.3-7.2). These findings indicate that host, but not donor,MTHFR genotypes modify the risk of acute
GVHD in recipients receiving MTX, in a manner consistent with our previously reported associations between
MTHFR genotypes and MTX toxicity. A direct trade-off between drug toxicity and drug efficacy may play a
role. Alternatively, the systemic folate environment, regulated by host tissues, might influence donor T-cell
growth and activity.
© 2006 American Society for Blood and Marrow Transplantation
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K. Robien et al.974NTRODUCTION
The antifolate drug methotrexate (MTX) is used
s an immunosuppressive agent after hematopoietic
ell transplantation (HCT) for acute graft-versus-host
isease (GVHD) prophylaxis. Folate plays a key role
s a methyl-group donor for DNA synthesis and thus
s a vital nutrient for rapidly replicating cells, such as
ematopoietic cells. We and others have found that
ome aspects of MTX treatment-related toxicity are
odiﬁed by key polymorphisms in the folate pathway
1,2]. A critical question is whether this greater sensi-
ivity to MTX corresponds to enhanced acute GVHD
rophylaxis. Before consideration of genotype-based
ose-adjustments to reduce toxicity in the HCT set-
ing, it is important to assess whether drug efﬁcacy
hanges by genotype.
Methylenetetrahydrofolate reductase (MTHFR)
atalyzes the irreversible conversion of 5,10-methyl-
netetrahydrofolate to 5-methyltetrahydrofolate and
irects the ﬂux of intracellular folate toward the con-
ersion of homocysteine to methionine at the expense
f nucleotide synthesis [3]. Two common non-synon-
mous genetic polymorphisms, C677T and A1298C,
ave been described for this enzyme. The homozy-
ous 677TT genotype, which occurs in approximately
0%-15% of Caucasian and Asian populations [4], has
een shown to have only 30%, and the heterozygous
CT ) genotype approximately 60% of the MTHFR
ild-type enzyme activity in vitro [5]. The 1298C
llele has also been found to result in decreased in
itro activity, although to a lesser extent than that seen
ith the 677T allele [6,7]. Approximately 5%-10% of
aucasians carry the 1298CC genotype [8], which re-
ults in an enzyme with approximately 90% of wild-
ype MTHFR activity [9]. We previously reported
hat individuals with the MTHFR 677TT genotype are
t increased risk of oral mucositis and delayed engraft-
ent after HCT [10,11], which are likely to reﬂect
TX toxicity to some extent.
Thymidylate synthase (TS) catalyzes the transfer
f a methyl group from 5,10-methylenetetrahydrofo-
ate to deoxyuridine monophosphate, creating deoxy-
hymidine monophosphate for DNA synthesis. A
olymorphic 28-base pair (bp) repeat in the 5=-un-
ranslated region of the TS gene [12] functions as
is-acting transcriptional enhancer element (TSER).
ouble (2R) and triple (3R) repeats are the most
ommon, but other numbers of repeats have been
eported [13]. Individuals with the 3R/3R genotype
ave been found to have greater mRNA expression
ompared with those with 2R/2R [12,14]. In addition,
functionally relevant 6-bp deletion polymorphism in
he 3= untranslated region (1494del6) [15] has been
ssociated with decreased mRNA stability [16].
In this study, we evaluated the effect of recipient
nd donor MTHFR and TS genotypes on risk of acute sVHD among adults who underwent allogeneic
CT for chronic myelogenous leukemia. We hypoth-
sized that recipient genotypes that confer a decreased
bility to recycle folate (eg, MTHFR 677TT, MTHFR
298CC, TSER 2R/2R, and TS 1494del6 /) would
e associated with lower risk of acute GVHD based on
revious reports of greater MTX toxicity with these
enotypes and thus presumably greater sensitivity to
he drug [10,11,17,18]. We also hypothesized that a
onor genotype associated with decreased ability to
ecycle folate would confer greater MTX efﬁcacy and
lower incidence of acute GVHD. We expected that
he donor genotype would be the more important
eterminant of risk of acute GVHD.
ETHODS
tudy Design and Recipient Population
Subjects in this retrospective cohort study were
dults undergoing allogeneic HCT at the Fred
utchinson Cancer Research Center (FHCRC; Seat-
le, Wash) between 1992 and 2002 who (1) had a
iagnosis of chronicmyelogenous leukemia in chronic or
ccelerated phase before transplantation, (2) were 18
ears of age at the time of transplantation, (3) received
ull myeloablative conditioning regimens with cyclo-
hosphamide/total body irradiation or busulfan/cyclo-
hosphamide, as previously described [19,20], (4) re-
eived all 4 scheduled doses of MTX, (5) did not
eceive leucovorin rescue, and (6) had DNA previ-
usly collected from pretransplantation peripheral
lood and available for analysis. All study participants
eceived MTX and cyclosporine for GVHD prophy-
axis according to previously described protocols [21].
one of the bone marrow or peripheral blood stem
ell infusions was depleted of T cells. Data collected
eferred to the ﬁrst transplantation if the study par-
icipant received 1 hematopoietic cell transplant.
his study was approved by the FHCRC institutional
eview board, and all study participants provided in-
ormed consent.
ata Collection
Medical records and patient databases were used
o abstract study data for each study participant. Data
ollected from the medical record included height,
eight, total dose of MTX received after transplanta-
ion, and total dose of leucovorin received. To verify
eproducibility of chart abstraction data, 13 charts
ere randomly selected and re-abstracted (blinded to
he results of the original abstraction); complete
greement between the 2 abstractions was conﬁrmed.
ata collected from patient databases included age,
ex, race, conditioning regimen, average busulfan con-
entration at steady state, donor relationship, donor
ex, and date of HCT.
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MTHFR, TS, and Risk of Acute GVHD 975aboratory Analyses
MTHFR and TS genotype frequencies were deter-
ined using polymerase chain reaction/restriction
ragment length polymorphism (MTHFR C677T ) or
aqMan assays (MTHFR C677T and A1298C, TSER,
S 1494del6) as reported previously [10,22]. All geno-
ype determinations were performed blinded to acute
VHD status.
etermination of Acute GVHD
Acute GVHD was diagnosed and peak severity
as graded according to standard criteria [23]. For
his analysis, acute GVHD incidence was coded as a
ichotomous variable (grade 1-4 acute GVHD versus
o detectable acute GVHD) because the majority of
he cohort had grade 2 acute GVHD, and there was
nsufﬁcient variation of acute GVHD grades within
he cohort to allow for stratiﬁcation. GVHD data
ere locked for analysis on July 11, 2005.
tatistical Analysis
Multivariable logistic regression analysis was used
o assess the association between genotypes and risk of
cute GVHD. We ﬁrst evaluated the risk of acute
VHD for each polymorphism (MTHFR C667T,
THFR A1298C, TSER, and TS 1494del6) individu-
lly, with the homozygous wild-type genotype for
ach polymorphism as the reference. Then we evalu-
ted risk of acute GVHD associated with the com-
ined MTHFR (C677T and A1298C ) or TS (TSER
nd TS 1494del6) genotype using individuals who
ere homozygous wild-type at both loci as the refer-
nce group for each analysis. Separate analyses were
erformed for recipient genotypes and for the geno-
ypes of the corresponding donors as the exposures of
nterest. Potential confounding factors (including age,
ex, race [Caucasian: yes/no], year of transplantation,
tage of chronic myelogenous leukemia at transplan-
ation, conditioning regimen, donor relationship,
ource of hematopoietic progenitor cells [bone mar-
ow versus peripheral blood], age, and sex) were eval-
ated by adding each factor to the unadjusted model
nd then assessing its effect on the odds ratio (OR)
ssociated with each genotype; a change of 10% was
egarded as sufﬁcient to include the variable in the
nal model. Age, donor relationship (related versus
nrelated), and year of transplantation met the criteria
or inclusion as covariates in the regression models.
estricting the analysis to Caucasians did not alter the
verall trends in the observed associations; thus, the
nalyses include data from Caucasian and non-Cauca-
ian recipients. Analyses were performed with SAS 9.1
SAS Institute, Cary, NC). A 95% conﬁdence interval
CI) excluding 1.0 or a 2-sided P value .05 was
onsidered statistically signiﬁcant. *ESULTS
Selected characteristics of the study population are
resented in Table 1. In total, 350 patients met the
riteria for inclusion in the study. DNA was available
or all eligible recipients, and 241 (69%) of their
onors. The recipient MTHFR C677T genotypes
ere not in the Hardy-Weinberg equilibrium (HWE;
 .03); however, this cohort did not meet the con-
itions required for HWE because it was a patient
roup rather than a random sample of the general
opulation. Donor MTHFR C677T and recipient and
onor MTHFR A1298C, TSER, and TS 1494del6 ge-
otypes were in HWE. Duplication of a random 10%
f the genotyping assays yielded 100% concordance.
Detectable acute GVHD occurred in 290 (83%)
f the study cohort. In most recipients, acute GVHD
ad grade 2 peak severity (Table 1). No relation be-
ween severity of oral mucositis and severity of acute
VHD was observed in this cohort. Oral mucositis
as evaluated prospectively for approximately half of
he cohort [10,11,24]; however, there were no statis-
ically signiﬁcant differences in Oral Mucositis Index
cores [25] when stratiﬁed by peak acute GVHD
able 1. Characteristics of the Recipient Population (n  350)*
emographics
Age (y) 40.4  9.2 (18-67)
Sex
Male 170 (56)
Female 134 (44)
Weight (kg) 79.8  17.3 (41.2-132.1)
Height (cm) 172.1  9.7 (146.1-195.5)
Body mass index (kg/m2) 26.9  5.3 (16.2-53.6)
Race
White 305 (87)
Non-white 45 (13)
ransplant information
Stage of CML at transplant
Chronic 305 (87)
Accelerated 45 (13)
Conditioning regimen
Cyclophosphamide/total body
irradiation 180 (51)
Busulfan/cyclophosphamide 170 (49)
Donor relationship
Related donors 180 (51)
HLA-matched 169 (94)
HLA-mismatched 11 (6)
Unrelated 1705 (49)
Source of hematopoietic
progenitor cells
Bone marrow 334 (95)
Peripheral blood 16 (5)
cute GVHD grade
0 60 (17)
1 31 (9)
2 200 (57)
3 52 (15)
4 7 (2)
ML indicates chronic myelogenous leukemia.
Mean  SD (range) or number of patients (%).
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K. Robien et al.976rade and adjusted for age and conditioning regimen
data not shown).
The variant MTHFR 677T allele in recipients was
ssociated with a statistically signiﬁcant trend toward
ecreased risk of any detectable acute GVHD
MTHFR 677CT: OR, 0.8; 95% CI, 0.4-1.6; MTHFR
77TT: OR, 0.4; 95% CI, 0.2-0.8; P for trend  .01;
able 2). The variant MTHFR 1298C allele in recip-
ents was associated with a statistically signiﬁcant in-
rease in acute GVHD risk compared with the wild-
ype MTHFR 1298AA genotype (1298AC: OR, 2.0;
5% CI, 1.1-3.9; 1298CC: OR, 3.6; 95% CI, 1.0-12.7;
for trend  .01). No association with acute GVHD
isk was observed for donor MTHFR genotypes (Ta-
le 2). Recipient and donor TS genotypes showed no
ssociation with acute GVHD risk, with the exception
f the donor TSER 3R/2R genotype, which showed a
tatistically signiﬁcant increased risk of acute GVHD
OR, 3.0; 95% CI, 1.3-7.2; Table 3).
Although not statistically signiﬁcant, analysis of
he combined recipient MTHFR C677T/A1298C ge-
otype showed similar patterns to the individual poly-
orphism analysis (Table 4). We were unable to as-
ess accurately the risk of acute GVHD by combined
onor MTHFR C677T/A1298C genotypes due to
mall numbers of certain haplotypes. Analysis of the
ecipient or donor combined TS genotypes by the
umber of variant alleles (0-1, 2, or 2 variant alleles)
howed no statistically signiﬁcant associations with
isk of acute GVHD (Table 3).
We previously reported no statistically signiﬁcant
ssociations between MTHFR C677T or A1298C ge-
otype and overall survival in this cohort (adjusted for
ge, stage of disease before transplantation, and donor
elationship) [26]. Because the inclusion criteria for
able 2. Risk of Acute GVHD by MTHFR Genotypes*
Recipient Genotype
OR (95% CI)
Donor Genotype
OR (95% CI)
THFR C677T
677CC 1.0 (reference) 1.0 (reference)
n  152 n  96
677CT 0.8 (0.4-1.6) 0.7 (0.3-1.6)
n  143 n  114
677TT 0.4 (0.2-0.8) 0.8 (0.3-2.4)
n  55 n  31
P for trend .01 .55
THFR A1298C
1298AA 1.0 (reference) 1.0 (reference)
n  172 n  117
1298AC 2.0 (1.1-3.9) 0.8 (0.4-1.8)
n  127 n  99
1298CC 3.6 (1.0-12.7) 0.9 (0.3-3.2)
n  38 n  23
P for trend <.01 .74
Adjusted for age, donor relationship (related versus unrelated), and
year of transplantation.his study required participants to have received all 4cheduled doses of MTX and no leucovorin rescue
severe or life-threatening toxicity is an indication for
ithholding doses of MTX or rescuing the patient
ith leucovorin), there is a low likelihood of MTX
oxicity-related early mortality in this study cohort.
ISCUSSION
This is the largest study to date to evaluate the
ffect of genetic variation in folate-related enzymes on
isk of acute GVHD after HCT, and the ﬁrst to
valuate the effect of the MTHFR A1298C, TSER, and
S 1494del6 genotypes. Strengths of our study design
nclude homogeneity in the study participants’ pre-
ransplantation diagnosis, treatment regimens, and
cute GVHD prophylaxis. Another strength is that we
sed multivariable analyses, which allowed us to adjust
or factors known to contribute to acute GVHD, such
s donor relationship.
In contrast to our ﬁndings, Pihusch et al [27]
eported no association between MTHFR C677T ge-
otype and risk of acute GVHD in their study of 89
llogeneic transplant recipients (compared with 304
eported in this study). However, it is difﬁcult to
ompare their ﬁndings with ours because their re-
earch focused on genes related to thromboembolic
omplications rather than response to MTX, and only
8% of the recipients in their study received MTX as
VHD prophylaxis (most received mycophenolate).
able 3. Risk of Acute GVHD by TS Genotypes*
Recipient Genotype
OR (95% CI)
Donor Genotype
OR (95% CI)
SER
TS 3R/3R 1.0 (reference) 1.0 (reference)
n  97 n  71
TS 3R/2R 1.4 (0.7-2.9) 3.0 (1.3-7.2)
n  159 n  108
TS 2R/2R 0.8 (0.4-1.6) 1.5 (0.6-3.9)
n  73 n  53
P for trend .55 .18
S 1494del6
6/6 1.0 (reference) 1.0 (reference)
n  149 n  104
6/6 1.1 (0.6-2.1) 0.8 (0.4-1.8)
n  141 n  106
6/6 0.7 (0.3-1.8) 0.9 (0.3-2.8)
n  39 n  26
P for trend .66 .72
S functional genotype
0-1 variant allele 1.0 (reference) 1.0 (reference)
n  150 n  101
2 variant alleles 0.5 (0.3-1.0) 1.1 (0.5-2.3)
n  141 n  110
>2 variant alleles 1.2 (0.4-3.5) 1.0 (0.3-4.1)
n  38 n  21
P for trend .51 .90
Adjusted for age, donor relationship (related versus unrelated), and
year of transplantation.
T
e
c
t
t
w
G
s
M
t
e
d
a
b
a
d
a
r
t
r
e
M
b
p
r
n
a
c
i
a
m
a
a
g
a
t
M
e
G
m
r
o
i
b
C
h
e
b
r
c
[
s
p
s
T
t
t
r
t
v
p
l
a
e
s
p
g
e
n
a
f
l
t
H
m
g
i
T
i
s
y
4
S
f
i
[
t
i
l
i
T
6
6
6
P
* d year
MTHFR, TS, and Risk of Acute GVHD 977heir study also included adult and pediatric recipi-
nts with a variety of hematologic malignancies and
onditioning regimens.
A recent report by Murphy et al [28] of 193 pa-
ients found that having an HLA-matched donor with
he MTHFR 677CT or TT genotype was associated
ith a decreased incidence of acute and chronic
VHD. No associations with GVHD risk were ob-
erved by recipient or HLA-mismatched donor
THFR C677T genotype. This study included pa-
ients who received myeloablative (68%) or nonmy-
loablative (32%) transplants, making comparisons
ifﬁcult because the GVHD experience is consider-
bly different between myeloablative and nonmyeloa-
lative treatment regimens [29]. Their study cohort
lso included patients who had MTX dose reductions
ue to severe mucositis or hepatic dysfunction (27%)
nd patients who received leucovorin rescue (53%).
We previously reported that the MTHFR 677TT
ecipient genotype is associated with increased early
oxicity after transplantation [10,11] and the 1298CC
ecipient genotype may be associated with decreased
arly toxicity after transplantation [11] in response to
TX (although this is not apparent when the com-
ined MTHFR genotypes are considered, which is
robably a more meaningful analysis). We currently
eport that individuals with the MTHFR 677TT ge-
otype appear to be at decreased risk of acute GVHD
nd individuals with the 1298CC genotype are at in-
reased risk of acute GVHD, as would be expected if
ncreased toxicity results from increased MTX activity
nd immunosuppression. Thus, the present results
irror, to some degree, the observed data on toxicity,
ssociating the 677TT genotype with greater toxicity
nd enhanced efﬁcacy (ie, reduced GVHD). The TS
enotypes appear to have no association with risk of
cute GVHD, but TS 1494del6 may confer increased
oxicity [11].
In contrast to our original hypothesis that the
THFR C677T and A1298C genotypes would have
ffects in similar directions with regard to acute
VHD risk, we found that the variants of each poly-
orphism were associated with opposite effects on
isk of acute GVHD. The precise biological relevance
f the MTHFR A1298C polymorphism is unclear, but
ts effects on in vitro enzyme activity have repeatedly
een shown to be less pronounced than that of the
able 4. Risk of Acute GVHD by Combined Recipient MTHFR C677T
1298AA 1
77CC 1.0 (reference) n  45 1.9 (0.
77CT 1.1 (0.4-3.0) n  74 1.4 (0.
77TT 0.5 (0.2-1.4) n  53 Not ob
for trend .19
Adjusted for age, donor relationship (related versus unrelated), an677T polymorphism [6,7,9]. In vivo, these ﬁndings 1ave been supported by studies showing little differ-
nce in plasma homocysteine or plasma folate levels
y MTHFR A1298C genotype [6,7,9,30,31], although
ed cell folate levels have been found to be signiﬁ-
antly higher in individuals with the 1298CC genotype
31]. Several epidemiologic studies have reported
tronger associations between the A1298C polymor-
hisms and various disease outcomes than those ob-
erved with the C677T polymorphism [26,32-35].
hus, the functional relevance of the A1298C geno-
ype may involve gene-environment or gene-gene in-
eractions not captured in vitro, or the variant may
esult in alterations in enzyme transcription, transla-
ion, or protein degradation. A study using a baculo-
irus expression system failed to identify a biochemical
henotype associated with the 1298C variant protein,
eading the investigators to suggest that the decreased
ctivity of the variant protein is the result of differ-
nces in protein stability [36]. Our ﬁndings demon-
trate the importance of evaluating both polymor-
hisms concurrently to understand fully the effect of
enetic variability in the MTHFR gene and avoid
rroneous conclusions.
We did not observe an association between ge-
etic variation in donor MTHFR and TS genotypes
nd acute GVHD risk. The systemic availability of
olate metabolites (speciﬁcally 5-methyltetrahydrofo-
ate) is regulated by MTHFR activity, and although
he hematopoietic cells are of donor origin after
CT, the majority of systemic MTHFR activity re-
ains that of the host tissues. Thus, recipientMTHFR
enotypes may play a vital role in the overall availabil-
ty of folate necessary for tissue repair and donor
-cell growth and activity. Decreased MTHFR activ-
ty associated with the 677TT genotype has been
hown to result in lower levels of circulating 5-meth-
ltetrahydrofolate in settings of low folate status [37-
0], as would be expected during MTX treatment.
tudies of the MTHFR A1298C polymorphism have
ailed to show any statistically signiﬁcant differences
n plasma 5-methyltetrahydrofolate levels by genotype
6,41,42].
Genetic variation may also modify other aspects of
he host tissue response, including tissue response to
nﬂammatory cytokines. MTHFR regulates intracel-
ular concentrations of tetrahydrofolate derivatives,
ncluding 10-formyltetrahydrofolate, which is a vital
8C Genotype*
1298CC P for Trend
 63 2.9 (0.7-12.2) n  38 .08
 64 Not observed
Not observed
of transplantation./A129
298AC
6-5.7) n
5-4.2) n
served-carbon group donor for purine biosynthesis; a reac-
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K. Robien et al.978ion catalyzed by 5-aminoimidazole-4-carboxamide ri-
onucleotide transformylase. Adenosine release into the
xtracellular space as a result of 5-aminoimidazole-4-
arboxamide ribonucleotide transformylase inhibition
nd accumulation of purine biosynthesis intermedi-
tes has emerged as an important mechanism by
hich MTX exerts anti-inﬂammatory activity [43].
he ﬁndings of this study on the MTHFR C677T
olymorphism support this hypothesis because de-
reased MTHFR activity among 677TT individuals
ould result in greater accumulation of purine in-
ermediates, increased release of adenosine, de-
reased local tissue inﬂammation, and decreased
cute GVHD. A better understanding of the func-
ional relevance of the A1298C polymorphism is
eeded before attempting to explain how this poly-
orphism might relate to the adenosine release
ypothesis.
Several groups have demonstrated that polygluta-
ated MTX selectively inhibits TS activity and in-
uces cell death in replicating cells due to a lack of
hymine (“thymine-less death”) [44-46]. This TS in-
ibition may explain our ﬁndings of a general lack of
ssociation between TS genotype and risk of acute
VHD. However, one would expect TS inhibition to
e dose-dependent as is seen with thymidylate syn-
hase inhibitors such as 5-ﬂuorouracil; individuals
ith the 3R/3R genotype (with greater TS expression)
hould exhibit less complete inhibition of TS than
ould be seen in individuals with the 2R/2R genotype.
n this study, only the donor TSER 3R/2R genotype
howed a statistically signiﬁcant association with acute
VHD risk, which we are unable to explain. Our
revious research found no difference in oral mucosi-
is scores by TSER genotype; however, the homozy-
ous variant TS 1494del6 6bp/6bp genotype was
ssociated with a statistically signiﬁcant increase in
ral mucositis compared with the homozygous wild-
ype TS 1494del6 genotype [11].
This is the largest study to date on the effects of
he MTHFR and TS genotypes on issues related to the
mmunosuppressive properties of MTX. However,
espite the relatively large sample, statistical power to
valuate interaction between the MTHFR and TS ge-
otypes or stratify by grade or site of acute GVHD
as limited. Even larger studies are needed to evaluate
he association between genotype and these details of
he acute GVHD experience.
The role of folate-mediated 1-carbon metabolism
n the risk of acute GVHD after HCT deserves fur-
her investigation, as does further elucidation of the
unctional relevance of the MTHFR A1298C vari-
nt. Although this study was limited to individuals
ho received MTX for acute GVHD prophylaxis,
he multifaceted role of folate in tissue replication
nd repair suggests that genetic variation in this
athway may have relevance in predicting outcomesn individuals who receive other forms of acute
VHD prophylaxis.
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